Suppr超能文献

迈向更有效的新冠肺炎预防策略(综述)

Towards a more effective strategy for COVID-19 prevention (Review).

作者信息

Szkaradkiewicz-Karpińska Anna K, Szkaradkiewicz Andrzej

机构信息

Department of Preclinical Conservative Dentistry and Preclinical Endodontics, University of Medical Sciences, 60-812 Poznań, Poland.

Institute of Health and Physical Culture, State Higher Vocational School, 64-100 Leszno, Poland.

出版信息

Exp Ther Med. 2021 Jan;21(1):33. doi: 10.3892/etm.2020.9465. Epub 2020 Nov 11.

Abstract

At the end of 2019, a new disease, similar to severe acute respiratory syndrome (SARS) associated with SARS-CoV was reported in Wuhan, China. It was quickly discovered that the etiological factor of the new disease (COVID-19) was a previously unknown SARS coronavirus 2 (SARS-CoV-2). The global spread of of COVID-19 has lead to the declaration of a pandemic status in 2019-2020 as declared by the World Health Organization and Public Health Emergency of International Concern. SARS-CoV-2 characterizes with high epidemic potential and is effectively disseminated between humans. SARS-CoV and SARS-CoV-2 are closely related pathogens. Their prime route of distribution is air-droplet transmission. Combating infectious diseases disseminated by inhalation is very difficult, and mainly relies on the use of vaccines. However, despite the lack of an effective anti-SARS-CoV vaccine and specific antiviral drugs, the strict sanitary procedures proved to be sufficient to stop the SARS epidemic in June 2003. However, epidemic research has indicated that SARS-CoV-2 is transmitted in humans significantly more effectively than SARS-CoV; therefore, the COVID-19 pandemic continues to expand. This indicates that the so far anti-epidemic activities to control COVID-19 are insufficient. In the current review, the possibility of using interferon α (IFN-α) as a preventive agent of COVID-19 is discussed. The current data concerning anti-COVID-19 vaccines and specific drugs against SARS-CoV-2 are also discussed. The aim of the current review is to contribute to the introduction of a more efficient strategy in the protection of the human population against COVID-19.

摘要

2019年底,中国武汉报告了一种与严重急性呼吸综合征(SARS)相似的新疾病,该疾病与SARS冠状病毒有关。很快发现,这种新疾病(COVID-19)的病因是一种此前未知的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)。COVID-19在全球的传播导致世界卫生组织宣布其在2019 - 2020年处于大流行状态,并构成国际关注的突发公共卫生事件。SARS-CoV-2具有高流行潜力,可在人与人之间有效传播。SARS-CoV和SARS-CoV-2是密切相关的病原体。它们的主要传播途径是空气飞沫传播。对抗通过吸入传播的传染病非常困难,主要依靠使用疫苗。然而,尽管缺乏有效的抗SARS-CoV疫苗和特异性抗病毒药物,但严格的卫生程序在2003年6月证明足以阻止SARS疫情。然而,流行病学研究表明,SARS-CoV-2在人与人之间的传播比SARS-CoV更有效;因此,COVID-19大流行仍在继续扩大。这表明到目前为止控制COVID-19的抗疫活动是不够的。在当前的综述中,讨论了使用干扰素α(IFN-α)作为COVID-19预防剂的可能性。还讨论了目前关于抗COVID-19疫苗和针对SARS-CoV-2的特异性药物的数据。当前综述的目的是为引入更有效的策略来保护人群免受COVID-19感染做出贡献。

相似文献

1
Towards a more effective strategy for COVID-19 prevention (Review).
Exp Ther Med. 2021 Jan;21(1):33. doi: 10.3892/etm.2020.9465. Epub 2020 Nov 11.
2
COVID-19 Outbreak in Malaysia.
Osong Public Health Res Perspect. 2020 Jun;11(3):93-100. doi: 10.24171/j.phrp.2020.11.3.08.
3
Preventive and treatment strategies of COVID-19: From community to clinical trials.
J Family Med Prim Care. 2020 May 31;9(5):2149-2157. doi: 10.4103/jfmpc.jfmpc_728_20. eCollection 2020 May.
4
Rescue of SARS-CoV-2 from a single bacterial artificial chromosome.
bioRxiv. 2020 Jul 22:2020.07.22.216358. doi: 10.1101/2020.07.22.216358.
5
Evaluation of the exposure risk of SARS-CoV-2 in different hospital environment.
Sustain Cities Soc. 2020 Oct;61:102413. doi: 10.1016/j.scs.2020.102413. Epub 2020 Jul 22.
7
COVID-19 Related Mortality During Management of a Hepatic Abscess.
J Radiol Nurs. 2020 Dec;39(4):271-274. doi: 10.1016/j.jradnu.2020.09.001. Epub 2020 Sep 22.
8
Could fighting airborne transmission be the next line of defence against COVID-19 spread?
City Environ Interact. 2019 Dec;4:100033. doi: 10.1016/j.cacint.2020.100033. Epub 2020 May 23.
9
Artemether, Artesunate, Arteannuin B, Echinatin, Licochalcone B and Andrographolide Effectively Inhibit SARS-CoV-2 and Related Viruses .
Front Cell Infect Microbiol. 2021 Aug 30;11:680127. doi: 10.3389/fcimb.2021.680127. eCollection 2021.
10
Excessive use of disinfectants against COVID-19 posing a potential threat to living beings.
Curr Res Toxicol. 2021;2:159-168. doi: 10.1016/j.crtox.2021.02.008. Epub 2021 Mar 4.

引用本文的文献

本文引用的文献

1
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.
J Virol. 2020 Nov 9;94(23). doi: 10.1128/JVI.01410-20.
2
Molecular diagnosis of COVID-19: Current situation and trend in China (Review).
Exp Ther Med. 2020 Nov;20(5):13. doi: 10.3892/etm.2020.9142. Epub 2020 Aug 25.
3
SARS-CoV-2 clearance in COVID-19 patients with Novaferon treatment: A randomized, open-label, parallel-group trial.
Int J Infect Dis. 2020 Oct;99:84-91. doi: 10.1016/j.ijid.2020.07.053. Epub 2020 Aug 3.
4
Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the Coronavirus Disease 2019 (COVID-19), a comprehensive literature review.
Diagn Microbiol Infect Dis. 2020 Sep;98(1):115094. doi: 10.1016/j.diagmicrobio.2020.115094. Epub 2020 May 30.
5
Coronavirus vaccine-associated lung immunopathology-what is the significance?
Microbes Infect. 2020 Oct;22(9):403-404. doi: 10.1016/j.micinf.2020.06.007. Epub 2020 Jun 26.
6
COVID-19 Vaccines: "Warp Speed" Needs Mind Melds, Not Warped Minds.
J Virol. 2020 Aug 17;94(17). doi: 10.1128/JVI.01083-20.
7
Inhibition of SARS-CoV-2 by type I and type III interferons.
J Biol Chem. 2020 Oct 9;295(41):13958-13964. doi: 10.1074/jbc.AC120.013788. Epub 2020 Jun 25.
8
Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway.
Virulence. 2020 Dec;11(1):805-810. doi: 10.1080/21505594.2020.1780088.
9
Immunology of COVID-19: Current State of the Science.
Immunity. 2020 Jun 16;52(6):910-941. doi: 10.1016/j.immuni.2020.05.002. Epub 2020 May 6.
10
The Challenges of Vaccine Development against a New Virus during a Pandemic.
Cell Host Microbe. 2020 May 13;27(5):699-703. doi: 10.1016/j.chom.2020.04.021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验